Development asset linked to BioMarin Pharmaceutical in public FDA and regional records.
biotech · NSCLC Stage IV · Poliomyelitis
BioMarin Pharmaceutical
Biotech Pharmaceutical Co.,
BioMarin Pharmaceutical drug portfolio — 37 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
770 Lindaro Street, San Rafael, CA 94901, US HQ
1997 Founded
3,171 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 770 Lindaro Street, San Rafael, CA 94901, US
- Founded
- 1997
- Employees
- 3,171
- Programs
- 40
- Drugs
- 37
- Patents
- 0
BioMarin Pharmaceutical pipeline
Portfolio lens on 37 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
BioMarin Pharmaceutical drug portfolio — 37 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: C55-isoprenyl pyrophosphate.
- Target
- C55-isoprenyl pyrophosphate
- Mechanism
- C55-isoprenyl pyrophosphate inhibitor
-
US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M1 antagonist
-
Development asset linked to BioMarin Pharmaceutical in public FDA and regional records.
-
Development asset linked to BioMarin Pharmaceutical in public FDA and regional records.
-
Development asset linked to BioMarin Pharmaceutical in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to BioMarin Pharmaceutical in public FDA and regional records.
-
Development asset linked to BioMarin Pharmaceutical in public FDA and regional records.
-
covid-19 vaccine (inactivated, adjuvanted, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in BioMarin Pharmaceutical's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
diphtheria (d), tetanus (t), pertussis (acellular, component) (pa), hepatitis b (rdna) (hbv), poliomyelitis (inactivated) (ipv) and haemophilus influenzae type-b (hib) conjugate vaccine (adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in BioMarin Pharmaceutical's portfolio.
-
Development asset linked to BioMarin Pharmaceutical in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
filgrastim
Antineoplastic and immunomodulating agents (L03)US regulatory status: approved. Molecular target: Granulocyte colony-stimulating factor receptor.
- Target
- Granulocyte colony-stimulating factor receptor
- Mechanism
- Granulocyte colony stimulating factor receptor agonist
-
Development asset linked to BioMarin Pharmaceutical in public FDA and regional records. Molecular target: Granulocyte colony-stimulating factor receptor.
- Target
- Granulocyte colony-stimulating factor receptor
- Mechanism
- Granulocyte colony stimulating factor receptor agonist
-
Development asset linked to BioMarin Pharmaceutical in public FDA and regional records.
-
Development asset linked to BioMarin Pharmaceutical in public FDA and regional records.
-
Development asset linked to BioMarin Pharmaceutical in public FDA and regional records.
-
influenza vaccine (h1n1)v (split virion, inactivated, adjuvanted)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in BioMarin Pharmaceutical's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
influenza vaccine (live attenuated, nasal)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in BioMarin Pharmaceutical's portfolio.
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
Development asset linked to BioMarin Pharmaceutical in public FDA and regional records.
-
Various (V04) compound in BioMarin Pharmaceutical's portfolio.
-
Development asset linked to BioMarin Pharmaceutical in public FDA and regional records. Molecular target: Bacterial DNA gyrase.
- Target
- Bacterial DNA gyrase
- Mechanism
- Bacterial DNA gyrase inhibitor
-
Development asset linked to BioMarin Pharmaceutical in public FDA and regional records. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
pegfilgrastim
Antineoplastic and immunomodulating agents (L03)US regulatory status: approved. Molecular target: Granulocyte colony-stimulating factor receptor.
- Target
- Granulocyte colony-stimulating factor receptor
- Mechanism
- Granulocyte colony stimulating factor receptor agonist
-
Development asset linked to BioMarin Pharmaceutical in public FDA and regional records.
-
Development asset linked to BioMarin Pharmaceutical in public FDA and regional records.
-
Development asset linked to BioMarin Pharmaceutical in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to BioMarin Pharmaceutical in public FDA and regional records.
-
Development asset linked to BioMarin Pharmaceutical in public FDA and regional records. Molecular target: Granulocyte colony-stimulating factor receptor.
- Target
- Granulocyte colony-stimulating factor receptor
- Mechanism
- Granulocyte colony stimulating factor receptor agonist
-
Development asset linked to BioMarin Pharmaceutical in public FDA and regional records.
-
Development asset linked to BioMarin Pharmaceutical in public FDA and regional records.
-
Development asset linked to BioMarin Pharmaceutical in public FDA and regional records.
-
Development asset linked to BioMarin Pharmaceutical in public FDA and regional records.
-
Development asset linked to BioMarin Pharmaceutical in public FDA and regional records.